FDA gives thumbs down on Valeant nail fungus drug
This article was originally published in Scrip
Executive Summary
Investors were not too heartbroken on 28 May about the complete response letter (CRL) the FDA dished out to Valeant Pharmaceuticals for its experimental nail fungus treatment efinaconazole, given Wall Street was more captivated by the Canadian company's agreement to acquire Bausch & Lomb for $8.7 billion.